Abstract
The secretion of oestrogens in premenopausal women is dependent on pituitary gonadotropin support. In oestrogen-dependent mammary carcinoma, ovariectomy is a suitable antihormonal treatment to prevent exposure of non-metastatic or metastatic tumor tissue to oestrogen stimulation and deprive the tissue of an important growth factor. In general, the benefit of castration is restricted to premenopausal women with recurrent or metastatic disease. In postmenopausal women, ovariectomy is only beneficial when a hormone-dependent lesion still depends in part on gonadotropin support. It is generally accepted, that oestrogen-receptor positive tumours will respond to ovariectomy or pharmacological suppression of ovarian activity, whereas the absence of oestrogen receptors in advanced breast carcinoma precludes antihormonal adjuvant treatment. However, the intrinsic difficulties of evaluating receptor status in tissue samples obtained at tumour resection or biopsy may warrant a therapeutic trial even when the presence of oestrogen receptors has not been confirmed.
This is a preview of subscription content, log in via an institution to check access.
Preview
Unable to display preview. Download preview PDF.
References
Akhtar BF, Marshall GR, Wickings EJ, Nieschlag E (1983) Reversible induction of azoospermia in rhesus monkeys by constant infusion of a gonadotropin-releasing hormone agonist using osmotic minipumps. J Clin Endocrinol Metab 56: 534–540
Blankenstein MA, Henkelman MS, Klijn GM (1985) Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells. Eur J Cancer Clin Oncol 21: 1493–1499
Clayton RN, Catt KJ (1981) Gonadotropin-releasing hormone receptors: characterization, physiological regulation, and relationship to reproductive function. Endocr Rev 2: 186–209
Christensen AK, Peacock KC (1980) Increase in Leydig cell number in testes of adult rats treated chronically with an excress of human chorionic gonadotrophin. Biol Reprod 22: 383–391
Conn PM, Hsueh AJW, Crowley WF (1984) Gonadotropin-releasing hormone: molecular and cell biology, physiology and clinical applications. Fed Proc 43: 2351–2361
Donaubauer HH, Kramer M, Krieg H, Mayer D, Rechenberg W v, Sandow J, Schütz E (1987) Investigations of the carcinogenicity of the LH-RH analogue buserelin (HOE 766) in rats using the subcutaneous route of administration. Fundam Appl Toxicol 9: 738–752
Foekens JA, Henkelman MS, Fukkink JF, Blankenstein MA, Klijn JGM (1986) Combined effects of buserelin, estradiol and tamoxifen on the growth of MCF-7 human breast cancer cells in vitro. Biochem Biophys Res Commun 140: 550–556
Fräser HM (1980) Inhibition of reproductive function by antibodies to luteinizing hormone releasing hormone. In: Hearn JP (ed) Immunological aspects of reproduction and fertility control. MTP Press, London, pp 143–171
Fraser HM (1983) Effect of treatment for one year with a luteinizing hormone-releasing hormone agonist on ovarian, thyroidal and adrenal function and menstruation in the stumptailed monkey (macaca arctoides). Endocrinology 112: 245–253
Fraser HM, Sandow J (1985) Suppression of follicular maturation by infusion of a luteinizing hormone releasing hormone agonist starting during the late luteal phase in the stumptailed macaque monkey. J Clin Endocrinol Metab 60: 579–584
Harvey HA, Lipton A, Max DT (1984) LH-RH analogs for human mammary carcinoma. In: Vickery BH, Nestor JJ, Hafez ESE (eds) LH-RH and its analogs, contraceptive and therapeutic applications. MTP Press, Lancaster, pp 329–335
Kitchell JP, Crooker SC, Wise DL, Zaneveld LJD (1984) Preparation of biodegradable levonorgestrel rods. In: Zatuchni GI, Goldsmith A, Shelton JD, Sciarra JJ (eds) Long-acting contraceptive delivery systems. Harper and Row, Philadelphia, pp 164–168
Klijn JGM, deJong FH, Lamberts SWJ, Blankenstein MA (1985) LH-RH agonist treatment in clinical and experimental human breast cancer. J Steroid Biochem 23: 867–873
Miller WR, Scott WN, Morris R, Fraser HM, Sharpe RM (1985) Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313: 231–233
Pelletier G, Dube D, Guy J, Segiun C, Lefebvre FA (1982) Binding and internalization of a luteinizing hormone-releasing hormone agonist by rat gonadotrophic cells. An autoradiographic study. Endocrinology 111: 1068–1076
Sandow J (1982) Gonadotropic and antigonadotropic actions of LH-RH analogues. In: Miiller EE, MacLeod RM (eds) Neuroendocrine perspectives, vol I. Elsevier Biomedical, Amsterdam, pp 339–395
Sandow J (1986) Therapeutic use of LH-RH analogs in reproductive disorders. In: Paulson JD, Negro-Vilar A, Lucena E, Martini L (eds) Andrology: interfertility and sterility. Academic Press, New Jersey, pp 15–37
Sandow J (1987) Pharmacology of LH-RH agonists. In: Furr BJA, Wakeling AE (eds) Pharmacology and clinical uses of inhibitors of hormone secretion and action. Bailliere Tindall, London, pp 365–384
Sandow J, Engelbart K, Rechenberg W v (1985) The different mechanisms for suppression of pituitary and testicular function. Medical Biol 63: 192–200
Sandow J, Seidel HR, Krauss B, Jerabek-Sandow G ( 1987 a) Pharmacokinetics of LH-RH agonists in different delivery systems. In: Klijn JGM, Paridaens R, Foekens JA (eds) Hormonal manipulation of cancer: peptides, growth factors and new (anti)steroidal agents. Raven Press, New York, pp 203 - 212
Sandow J, Fraser HM, Seidel H, Krauss B, Jerabek-Sandow G, Rechenberg W v (1987b) Buserelin pharmacokinetics, metabolism and mechanisms of action. Br J Clin Pract 41 (Suppl. 48) 6–13
Schally AV, Comaru-Schally AM, Redding TW (1984) Antitumor effects of analogs of hypothalamic hormones in endocrine-dependent cancers. Proc Soc Exp Biol Med 175: 259–281
Walker KJ, Turkes A, Williams MR, Blarney RW, Nicholson RI (1986) Preliminary endocrinological evaluation of a sustained-release formulation of the LH-releasing hormone agonist (D-Ser (Bu)6Azgly10LH-RH in premenopausal women with advanced breast cancer. J Endocrinol 111: 349–353
Waxman JH, Sandow J, Man A, Barnett MJ, Hendry WF, Besser GM, Oliver RTD, Magill PJ (1986) The first clinical use of depot buserelin for advanced prostatic carcinoma. Cancer Chemother Pharmacol 18: 174–175
West C, Baird DT (1987) Suppression of ovarian activity by Zoladex depot (ICI 118630), a long-acting LH-RH agonist analogue. Clin Endocrinol 26: 213–220
Wise DL, Fellmann TD, Sanderson JE, Wentworth RL (1979) Lactic/glycolic acid polymers. In: Gregoriadis G (ed) Drug carriers in biology and medicine. Academic Press, London, pp 237–270
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Sandow, J., Fraser, H.M., Engelbart, K., Seidel, H., Donaubauer, H., von Rechenberg, W. (1988). Preclinical Studies on Suppression of Follicular Maturation and Oestrogen Secretion in Rats and Monkeys. In: Höffken, K. (eds) LH-RH Agonists in Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73530-1_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-73530-1_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73532-5
Online ISBN: 978-3-642-73530-1
eBook Packages: Springer Book Archive